Soleno Therapeutics, Inc. - SLNO Total Company Value-to-Revenue Ratio

Soleno Therapeutics, Inc. (SLNO) - corporate logo

Anticipation of drug approvals caused a cash deficit, which triggered a spike on the Soleno Therapeutics (SLNO) EV/Sales chart. The 8987.61 metric confirms the current level of market valuation. Business stability is based on outsourcing production through contract manufacturing plants, while intellectual potential is provided by high-paid endocrinologists creating unique medications for rare metabolic pathologies.

SLNO Soleno Therapeutics: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 05/30/2026

SLNO (soleno.life): analytical breakdowns and indicator data

- cash and cash flow indicators:
Initial company analysis:Soleno Therapeutics - SLNO
Original product of Soleno Therapeutics

This indicator determines the enterprise value of the entire business, accounting for net debt, and compares it to sales volume to identify whether the asset is overvalued or undervalued. By analyzing the ratio of enterprise value to annual revenue, an investor can see the premium for the monopoly status of Soleno Therapeutics (SLNO), driven by the patent protection of orphan drugs, which makes the asset resilient to competition and justifies high multiples.

Competitor analysis for Soleno Therapeutics

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|FOLD - Enterprise Value-to-Revenue Ratio|ETNB: Enterprise Value-to-Revenue Ratio|AGIO: EV/Sales Multiple|Structure Therapeutics Inc. - Business Value to Revenue|MDXG (MiMedx Corp) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Rezolute Inc RZLT|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)